Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
November 01, 2022 06:30 ET
|
Pyxis Oncology
Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2022 17:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology company focused on developing an arsenal of next-generation therapeutics to target...
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
August 15, 2022 07:00 ET
|
Pyxis Oncology
• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a senior biotech...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2022 06:45 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers,...
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
June 28, 2022 06:35 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today...
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
May 19, 2022 06:35 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat...
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
May 13, 2022 08:03 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat...
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference
April 27, 2022 06:35 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to...
Pyxis Oncology Announces Leadership Changes
April 13, 2022 06:35 ET
|
Pyxis Oncology
- Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer - - Jan Pinkas, Ph.D., promoted to Chief Scientific Officer - - Company continues to advance programs toward the clinic with IND...
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022 13:05 ET
|
Pyxis Oncology
- Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and...